

The Ensign Group, Inc. (ENSG)

\$34.15 (As of 05/04/20)

Price Target (6-12 Months): **\$39.00**

Long Term: 6-12 Months

Zacks Recommendation: **Outperform**
(Since: 02/10/20)

Prior Recommendation: Neutral

Short Term: 1-3 Months

Zacks Rank: (1-5) **2-Buy**

Zacks Style Scores: VGM:A

Value: A | Growth: A | Momentum: A

Summary

Ensign Group's spin-off of its home health and hospice business is expected to help it meet the patients' requirements as well as enhance shareholder's value. Its historical growth has been driven by its expertise in acquiring real estate or leasing post-acute care operations and transforming them into market leaders. Its inorganic strategies have boosted its revenue base and a solid financial health enables it to enhance shareholder value. Its financial flexibility continues to impress. Frequent share repurchases and dividend payments at regular intervals have helped it retain investors' confidence in this stock. Its shares have outperformed its industry in a year's time. However, it has been suffering from rising expenses that keep draining its bottom line.


Price, Consensus & Surprise



Data Overview

52 Week High-Low	\$58.39 - \$24.06
20 Day Average Volume (sh)	407,467
Market Cap	\$1.8 B
YTD Price Change	-24.7%
Beta	0.77
Dividend / Div Yld	\$0.20 / 0.6%
Industry	Medical - Nursing Homes
Zacks Industry Rank	Top 4% (11 out of 253)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	9.1%
Last Sales Surprise	3.0%
EPS F1 Est- 4 week change	0.0%
Expected Report Date	05/04/2020
Earnings ESP	0.0%
P/E TTM	15.3
P/E F1	13.4
PEG F1	0.9
P/S TTM	0.8

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2021	613 E	615 E	625 E	635 E	2,581 E
2020	579 E	588 E	604 E	620 E	2,390 E
2019	549 A	576 A	601 A	560 A	2,037 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2021	\$0.69 E	\$0.68 E	\$0.70 E	\$0.74 E	\$2.80 E
2020	\$0.62 E	\$0.61 E	\$0.63 E	\$0.68 E	\$2.55 E
2019	\$0.55 A	\$0.54 A	\$0.55 A	\$0.60 A	\$2.24 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 05/04/2020. The reports text is as of 05/05/2020.

Overview

Founded in 1999 and headquartered in Mission Viejo, CA, The Ensign Group Inc. provides health care services in the post-acute care continuum, urgent care center and mobile ancillary businesses in the U.S.


The company provides health care services across the post-acute care continuum and ancillary businesses in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oklahoma, Oregon, South Carolina, Texas, Utah, Washington, Wisconsin and Wyoming. As of Dec 31, 2019, it offered skilled nursing, senior living and rehabilitative care services through 223 skilled nursing and senior living facilities. Of the 223 facilities, the company operated 161 facilities under long-term lease arrangements with options to purchase 11 of those 161 facilities. It also owned an additional 90 real estate properties.

Recently, the company authorized the separation of its home health and hospice business and also all its senior living operations from the parent company into a separate publicly traded entity. On its completion, there are two different companies, namely The Ensign Group, Inc. that will consist of the transitional and skilled services, rehabilitative care services, healthcare campuses, post-acute-related new business endeavors and real estate investments, and The Pennant Group, Inc., which will comprise the company's home health and hospice business line and substantially, all its senior living operations.

The company now operates through two services lines, namely Transitional and Skilled Services and Other.

Transitional and Skilled Services: As of Dec 31, 2019, its skilled nursing companies provided skilled nursing care at 213 operations with 22,625 operational beds in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin.

Other: This service line consists of senior living operations, real estate properties, mobile diagnostics and other ancillary operations.



Reasons To Buy:

- ▲ **Solid Outlook:** For the full year, share guidance is expected between \$2.50 and 2.58 per share, up from the earlier band of \$2.22-\$2.30 per share. The company expects revenues in the \$2.42-\$2.45 billion band, up from the \$2.30-\$2.35 bracket. This strong guidance should instill investor's confidence in the company.
- ▲ **Inorganic Growth:** The company boasts a strong inorganic growth story with several acquisitions in the past decade. Its historical growth has been mainly driven by its expertise in acquiring real estate or leasing post-acute care operations and transforming them into market leaders. With each acquisition, the company had sharpened its expertise, both clinically and financially. Ensign continues to actively seek transactions to acquire real estate and to lease both well-performing and struggling skilled nursing, assisted living and other healthcare related businesses in new and existing markets. During 2019, it expanded its portfolio with 22 stand-alone skilled nursing operations, one stand-alone senior living operation and four campus operations. These operations added a total of 3,142 operational skilled nursing beds and 407 operational senior living units. We expect all these buyouts to bode well for the long haul.
- ▲ **Growing Revenues:** The Ensign Group's top line has been growing since 2012. Revenues witnessed a six-year CAGR (2012-18) of 16.3%. This upside continued in 2019 with the metric rising 16.1% year over year, driven by both its Medicaid and Medicare businesses. The company's growth strategies and acquisitions are likely to drive the top line. It also anticipates 2020 annual revenues in the band of \$2.42-\$2.45 billion, the midpoint indicating an upside of 6.3% from the year-ago reported figure.
- ▲ **Capital Deployment:** The company has been taking up several initiatives in order to efficiently deploy capital. Frequent share repurchases and dividend payments at regular intervals have helped the company retain investors' confidence in this stock. Ensign Group has been a dividend-paying company since 2002 and has increased its payout annually for the past 17 years. The company's dividend yield stands at 0.6%, higher than the industry average of 0.4%. We believe the company's financial strength to continue buoying investors' confidence in the stock.
- ▲ **Divestiture:** The company recently separated its home health and hospice business into a separate publicly-traded company. This spin-off is expected to meet the patients' requirements and also be beneficial to the shareholders. The company hopes that it will be able to add value to its home health, senior living and hospice business line from this spin-off. We expect this divestiture to enable Ensign Group to focus on its core operations.
- ▲ **Capital Position:** The company's balance sheet position also remains a positive. Its net debt is 66% of capital, much lower than industry's average of 106.2%. Also, its time interest earned stands at 8.4x, much higher than the industry's average of 0.3x. As of Dec 31, 2020, it had cash and cash equivalents of \$59.2 million and \$135 millions of revolving line of credit, higher than the current maturities of long-term debt of \$2.7 million. Thus, its financial flexibility is impressive.
- ▲ **Price Performance:** In a year's time, shares of Ensign Group have lost 34.4%, lower than its industry's decline of 40%. Its solid fundamentals such as divestitures and growing revenues should help the stock bounce back going forward.

Promising Post-Acute Care industry, competitive strength, inorganic growth, strong underwriting Results and efficient capital deployment pave the way for long term growth.

Risks

- **Rising Expenses:** The company has been witnessing a persistent increase in total expenses since 2012. The same was up 8.2% year over year in 2018 due to higher cost of services, selling, general & administrative expenses, etc. Expenses again rose 14.2% year over year in 2019 due to higher cost of services, general and administrative expenses and rent-cost of services. The rising trend in expenses continues to hurt the company, denting its bottom line.
 - **Overvalued:** The stock is trading at a premium to its industry average. Its current price-to-sales value stands at 0.8x, much above the industry's average of 0.4x. This makes its valuation expensive.
-

Last Earnings Report

Ensign Group's Q4 Earnings Beat Estimates, Rise Y/Y

Ensign Group delivered adjusted operating earnings of 60 cents per share in fourth-quarter 2019, beating the Zacks Consensus Estimate by 9.1%. Also, the metric improved 11.1% year over year on higher revenues.

Moreover, adjusted net income in the quarter under review was \$27.4 million, up 3.9% from the prior-year quarter.

Quarter Ending **12/2019**

Report Date	Feb 05, 2020
Sales Surprise	3.04%
EPS Surprise	9.09%
Quarterly EPS	0.60
Annual EPS (TTM)	2.24

Operational Update

Total revenues of \$560 million increased 21.1% year over year in the reported quarter. Moreover, the metric beat the Zacks Consensus Estimate by 2.9%.

Total expenses escalated 18.7% year over year to \$520 million due to higher cost of services, rent, general and administrative expenses plus depreciation and amortization.

Interest expense of the company rose 11.8% year over year.

Financial Update

The company exited 2019 with \$59 million of cash and cash equivalents, up 90.6% from the level at 2018 end.

As of Dec 31, 2019, long-term debt less current maturities was \$325 million, up 39.5% from the level at 2018 end.

For 2019, net cash from operating activities stands at \$168.9 million, down 0.7% year over year.

Dividend Update

Ensign Group paid out a quarterly cash dividend of 5 cents per share during the fourth quarter. The company has been hiking its dividend for the 17 consecutive years.

2020 Outlook

Following solid fourth-quarter earnings, management again raised its 2020 guidance.

For the full year, earnings per share are expected between \$2.50 and 2.58 on revenues within \$2.42-\$2.45 billion.

Recent News

Ensign Group Expands Colorado Presence With Twin Buyouts – Mar 3, 2020

Ensign Group completed the buyouts of the operations of two skilled nursing facilities located in Commerce City, CO. Subject to long-term, triple net leases, the transactions were effective Mar 1, 2020. The addition of Ridgeview Post Acute, a skilled nursing facility with 105 skilled nursing beds, and Irondale Post Acute, a skilled nursing facility with 83 skilled nursing beds, adds 216 skilled nursing operations to the company's portfolio.

Ensign Group Takes Shareholder-Friendly Initiatives – Dec 17, 2019

In an effort to enhance shareholder value, the board of directors of Ensign Group has proposed a 5.3% increase in the quarterly dividend of 4.75 cents per share. This translates to a yearly dividend payment of 5 cents per share. Shareholders of record on Dec 31, 2019 are expected to receive this meatier dividend on or before Jan 31, 2019.

Ensign Group Acquires Facilities to Boost Portfolio – Dec 3, 2019

Ensign Group acquired four skilled nursing facilities in Dallas, TX. Effective Dec 1, 2019, the purchases will be subject to long-term, triple net leases with purchase options following year five of the lease. Ensign Group also purchased the real estate and operations of Mission Hills Post Acute in Mesa, AZ, which will further bolster its portfolio.

Ensign Group Acquires Nursing Facilities in Texas — Nov 4, 2019

Ensign Group acquired the real estate and the operations of Treasure Hills Healthcare and Rehabilitation Center in Harlingen, TX, Keller Oaks Healthcare Center in Keller, TX and Kirkwood Manor in Braunfels, TX. The transactions were effective Nov 1, 2019.

Valuation

The Ensign Group's shares are down 25% and 34.4% in the year-to-date period and over the trailing 12-month period, respectively. Stocks in the Zacks sub-industry and the Zacks Finance sector are down 36.2% and 6% in the year-to-date period, respectively. Over the past year, the Zacks sub-industry and sector are down 40% and 3.2%, respectively.

The S&P 500 index is down 12.1% in the year-to-date period and 3.7% in the past year.

The stock is currently trading at 0.75x price to sales value, which compares to 0.43x for the Zacks sub-industry, 2.66x for the Zacks sector and 3.20x for the S&P 500 index.

Over the past five years, the stock has traded as high as 1.31x and as low as 0.48x, with a 5-year median of 0.76x. Our Outperform recommendation indicates that the stock will perform better than the market. Our \$39 price target reflects 0.86x sales.

Industry Analysis Zacks Industry Rank: Top 4% (11 out of 253)



Top Peers

Company (Ticker)	Rec	Rank
Genesis Healthcare, Inc. (GEN)	Outperform	NA
Acadia Healthcare Company, Inc. (ACHC)	Neutral	4
Brookdale Senior Living Inc. (BKD)	Neutral	3
Capital Senior Living Corporation (CSU)	Neutral	NA
Magellan Health, Inc. (MGLN)	Neutral	3
Tenet Healthcare Corporation (THC)	Neutral	3
Universal Health Services, Inc. (UHS)	Neutral	4
UnitedHealth Group Incorporated (UNH)	Neutral	3

Industry Comparison Industry: Medical - Nursing Homes				Industry Peers		
	ENSG	X Industry	S&P 500	ACHC	MGLN	UHS
Zacks Recommendation (Long Term)	Outperform	-	-	Neutral	Neutral	Neutral
Zacks Rank (Short Term)	2	-	-	4	3	4
VGM Score	A	-	-	B	B	B
Market Cap	1.83 B	115.96 M	19.65 B	1.91 B	1.56 B	8.53 B
# of Analysts	3	.5	14	7	3	6
Dividend Yield	0.59%	0.00%	2.19%	0.00%	0.00%	0.81%
Value Score	A	-	-	A	B	B
Cash/Price	0.04	0.41	0.06	0.06	0.39	0.01
EV/EBITDA	16.61	13.65	11.76	10.81	6.37	7.27
PEG Ratio	0.89	0.89	2.48	0.95	0.92	2.09
Price/Book (P/B)	2.78	1.27	2.63	0.76	1.09	1.56
Price/Cash Flow (P/CF)	10.80	2.15	10.38	5.38	6.86	6.17
P/E (F1)	13.39	13.41	18.81	10.81	16.69	13.94
Price/Sales (P/S)	0.80	0.07	2.02	0.61	0.22	0.75
Earnings Yield	7.47%	-19.55%	5.07%	9.27%	5.98%	7.17%
Debt/Equity	1.98	0.24	0.73	1.44	0.49	0.73
Cash Flow (\$/share)	3.16	0.93	7.01	4.01	9.10	15.94
Growth Score	A	-	-	C	C	B
Hist. EPS Growth (3-5 yrs)	14.58%	10.57%	10.87%	-0.20%	-0.44%	9.76%
Proj. EPS Growth (F1/F0)	13.69%	-6.26%	-8.14%	-2.17%	0.36%	-29.31%
Curr. Cash Flow Growth	18.22%	6.85%	5.88%	-2.61%	14.08%	2.58%
Hist. Cash Flow Growth (3-5 yrs)	16.88%	-6.54%	8.55%	24.05%	3.37%	23.60%
Current Ratio	1.20	0.82	1.25	1.17	1.84	1.09
Debt/Capital	66.44%	66.44%	44.07%	59.24%	32.70%	42.32%
Net Margin	4.84%	-1.41%	11.00%	3.61%	0.78%	6.34%
Return on Equity	17.32%	-3.78%	16.43%	7.41%	6.81%	14.89%
Sales/Assets	0.99	0.97	0.55	0.46	2.31	0.98
Proj. Sales Growth (F1/F0)	4.59%	0.00%	-1.76%	4.27%	0.50%	-5.58%
Momentum Score	A	-	-	B	C	F
Daily Price Chg	-6.34%	-2.95%	-0.01%	-3.96%	-8.10%	-0.73%
1 Week Price Chg	0.16%	0.00%	0.53%	0.81%	26.04%	-2.46%
4 Week Price Chg	-5.35%	1.54%	6.66%	22.06%	27.90%	2.00%
12 Week Price Chg	-35.89%	-34.61%	-20.38%	-35.18%	-13.45%	-29.50%
52 Week Price Chg	-34.37%	-42.30%	-13.44%	-36.19%	-11.59%	-20.93%
20 Day Average Volume	407,467	166,643	2,567,149	875,594	179,096	663,084
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	-5.67%	0.00%	-28.30%
(F1) EPS Est 4 week change	0.00%	-15.14%	-6.96%	-9.70%	-0.97%	-31.86%
(F1) EPS Est 12 week change	13.11%	-24.43%	-13.90%	-14.35%	-20.41%	-34.14%
(Q1) EPS Est Mthly Chg	0.00%	0.00%	-13.62%	-15.13%	0.00%	-78.31%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.